Leonteq Securities AG’s Acadia Pharmaceuticals ACAD Stock Holding History

Leonteq Securities AG’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.4K	Buy	1,832 +293	+19%	+$6.45K	﹤0.01%	822
2026 Q1	$34.3K	Sell	1,539 -417	-21%	-$9.96K	﹤0.01%	914
2025 Q4	$52.2K	Sell	1,956 -1,653	-46%	-$39.5K	﹤0.01%	947
2025 Q3	$77K	Buy	3,609 +1,257	+53%	+$29.7K	﹤0.01%	801
2025 Q2	$50.7K	Buy	2,352 +52	+2%	+$967	﹤0.01%	846
2025 Q1	$38.2K	Buy	2,300 +444	+24%	+$8.07K	﹤0.01%	872
2024 Q4	$34.1K	Buy	+1,856	New	+$30K	﹤0.01%	895
2021 Q1	–	Sell	-6,857	Closed	-$367K	–	974
2020 Q4	$367K	Buy	+6,857	New	+$340K	0.02%	460

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Leonteq Securities AG's ACAD Position: Q2 2026 in Review

Leonteq Securities AG increased its Acadia Pharmaceuticals (ACAD) stake by 19% in Q2 2026, buying an estimated $6.45K and bringing the position to 1,832 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #822.

Leonteq Securities AG first reported a position in ACAD in Q4 2020 and has held it in 8 quarters since. The position peaked at $367K in Q4 2020. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Leonteq Securities AG held 1,832 shares of Acadia Pharmaceuticals worth $46.4K as of Q2 2026.
Leonteq Securities AG bought 293 Acadia Pharmaceuticals shares in Q2 2026, an estimated $6.45K.
Acadia Pharmaceuticals made up ﹤0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #822 holding.
Leonteq Securities AG first reported a position in Acadia Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
Leonteq Securities AG's Acadia Pharmaceuticals position peaked at $367K in Q4 2020.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.